China Universal Asset Management Co. Ltd. Acquires 6,314 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

China Universal Asset Management Co. Ltd. lifted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 11.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 63,358 shares of the biopharmaceutical company’s stock after buying an additional 6,314 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Amicus Therapeutics were worth $597,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in FOLD. Wellington Management Group LLP raised its stake in shares of Amicus Therapeutics by 13.5% in the third quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock worth $255,936,000 after acquiring an additional 2,856,101 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Amicus Therapeutics by 1.2% in the third quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company’s stock valued at $70,499,000 after purchasing an additional 80,926 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in Amicus Therapeutics by 4.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,160,027 shares of the biopharmaceutical company’s stock worth $33,749,000 after purchasing an additional 139,491 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Amicus Therapeutics by 10.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company’s stock worth $28,486,000 after buying an additional 242,672 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in Amicus Therapeutics by 141.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company’s stock valued at $21,765,000 after buying an additional 1,192,489 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Bank of America boosted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. Guggenheim upped their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research note on Monday, January 13th. JPMorgan Chase & Co. boosted their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $16.88.

Insider Activity

In related news, CEO Bradley L. Campbell sold 7,901 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $11,083,175. The trade was a 0.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.20% of the stock is owned by company insiders.

Amicus Therapeutics Stock Down 0.6 %

Shares of NASDAQ:FOLD opened at $9.58 on Monday. The company has a 50 day moving average price of $9.64 and a two-hundred day moving average price of $10.47. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. The company has a market capitalization of $2.86 billion, a PE ratio of -28.18, a PEG ratio of 1.54 and a beta of 0.62. Amicus Therapeutics, Inc. has a 52 week low of $8.78 and a 52 week high of $14.03.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.